Summary
The claims provided do not align with the supplied FDA label content. The provided label excerpts address thyroid C-cell tumor risk (boxed warning/contraindications) and do not support the gastrointestinal/burping incidence, mechanisms, comparisons to semaglutide, or titration/timeline assertions.
Category Scores
Accurate Statements
Unsupported Statements
Burping (eructation) is a reported side effect of Mounjaro (tirzepatide).
The supplied label excerpts (thyroid C-cell tumors risk section, contraindications, carcinogenesis, and counseling) do not mention burping/eructation.
Mounjaro (tirzepatide) is a GLP-1/GIP receptor agonist for type 2 diabetes and weight management.
The supplied label excerpts do not include indication language or mechanism details (GLP-1/GIP) or weight management labeling.
Gastrointestinal issues like burping (eructation), bloating, and gas are listed as common side effects of Mounjaro, affecting 1-10% of users.
The supplied label excerpts do not provide GI adverse reaction prevalence (1–10%) or list these GI symptoms as common.
Burping from Mounjaro is associated with slowing of gastric emptying, which traps air and gases in the stomach.
No mechanism relating burping to gastric emptying or trapping air/gases is present in the supplied label excerpts.
In the SURPASS trials, burping occurred in about 4-7% of patients on 10-15 mg tirzepatide weekly doses.
The supplied label excerpts do not contain SURPASS trial incidence data for burping by dose.
In the SURPASS trials, burping occurred in about 2-3% of patients on placebo.
The supplied label excerpts do not contain placebo burping incidence data from SURPASS.
Burping on Mounjaro is dose-dependent.
No dose-response burping information is included in the supplied label excerpts.
Burping often starts within the first weeks of Mounjaro treatment.
No timeline/onset information for burping is included in the supplied label excerpts.
Burping peaks during dose escalation on Mounjaro.
No dose-escalation temporal pattern for burping is included in the supplied label excerpts.
Mounjaro delays stomach emptying by up to 30-50%.
No quantitative effect on gastric emptying (30–50%) is included in the supplied label excerpts.
Mounjaro increases swallowed air retention.
No statement about swallowed air retention is included in the supplied label excerpts.
Mounjaro can increase fermentation of undigested food by gut bacteria.
No statement about gut bacterial fermentation is included in the supplied label excerpts.
The increased gas from Mounjaro is released as burps.
No mechanistic link between increased gas and burps is included in the supplied label excerpts.
High-fat meals worsen burping associated with Mounjaro.
No dietary modifier information is included in the supplied label excerpts.
Carbonated drinks worsen burping associated with Mounjaro.
No dietary/beverage modifier information is included in the supplied label excerpts.
Mounjaro delays stomach emptying by up to 30-50% by mechanism.
No mechanism or quantitative gastric emptying effect is included in the supplied label excerpts.
Mounjaro can produce GI motility changes via dual GIP action that may amplify GI motility changes compared with pure GLP-1 drugs.
No discussion of dual GIP action, GI motility changes, or comparison to pure GLP-1 drugs is included in the supplied label excerpts.
Burping typically eases after 4-8 weeks as the body adjusts to Mounjaro.
No duration-adjustment statement for burping is included in the supplied label excerpts.
Burping persists in 10-20% of long-term users of Mounjaro.
No long-term user persistence rate for burping is included in the supplied label excerpts.
Starting at lower doses (2.5 mg) and titrating slowly reduces onset of burping.
No dosing/titration guidance or burping reduction effect is included in the supplied label excerpts.
If burping continues beyond 12 weeks, it signals poor tolerance of Mounjaro.
No tolerance interpretation for persistent burping beyond 12 weeks is included in the supplied label excerpts.
5-10% of users discontinue Mounjaro due to gastrointestinal effects.
No discontinuation rates due to GI effects are included in the supplied label excerpts.
Severe or bloody burping with pain, vomiting, or weight loss unrelated to the drug warrants checking for gastroparesis.
No guidance linking burping characteristics to gastroparesis evaluation is included in the supplied label excerpts.
Gastroparesis is described as rare with GLP-1 agonists, with an approximate risk of ~1%.
No gastroparesis incidence or comparative statement is included in the supplied label excerpts.
Burping warrants checking for pancreatitis in the setting described.
No pancreatitis evaluation guidance related to burping is included in the supplied label excerpts.
Mounjaro users report burping rates of 5-8%.
No burping rate information is included in the supplied label excerpts.
Semaglutide (Ozempic) users report burping rates of 3-6%.
No semaglutide/Ozempic comparative adverse reaction rates are included in the supplied label excerpts.
Mounjaro burping rates may be similar to or slightly higher than semaglutide burping rates.
No comparison between tirzepatide and semaglutide for burping rates is included in the supplied label excerpts.
Mounjaro is associated with less nausea than semaglutide.
No comparative nausea information is included in the supplied label excerpts.
Both Mounjaro and semaglutide have less gas overall than older diabetes drugs like metformin.
No comparative gas/adverse reaction information vs metformin is included in the supplied label excerpts.
Contradictions
Low
AI Statement
Mounjaro (tirzepatide) is a GLP-1/GIP receptor agonist for type 2 diabetes and weight management.
Label Reference
Supplied label excerpt sections are limited to thyroid C-cell tumor risk (5.1), contraindications (4), carcinogenesis (13.1), and counseling (17). The provided excerpts do not establish GLP-1/GIP mechanism or indication language.
Important Omissions
No statements in the provided claims address the supplied label’s core boxed warning topic: risk of thyroid C-cell tumors in rats, the associated counseling, and the contraindication in patients with personal/family history of MTC or MEN 2.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
High
Many claims are unsupported by the supplied prescribing information and include specific incidence rates, mechanisms, dose/timing patterns, and evaluation guidance (e.g., gastroparesis/pancreatitis checks). With only the supplied thyroid C-cell tumor label excerpts available, these additional GI-related safety assertions cannot be verified against the label content provided.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Not Aligned
Primary Issue
All major claims concern burping/GI incidence, mechanisms, trial-specific rates, comparisons to semaglutide/metformin, and clinical evaluation/titration guidance—none of which are supported by the supplied FDA label excerpts.
Suggested Improvement
Limit statements to what is contained in the supplied label sections (thyroid C-cell tumor risk, contraindications for MTC/MEN 2, uncertainty of human relevance, and related counseling/monitoring language). If GI/burping claims are required, provide the corresponding FDA label sections (e.g., Adverse Reactions and Warnings/Precautions for GI events) to support them.